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Background: High endothelial venules (HEV) have been recognized to play a role in metastasis by its changes seen
in the cancer microenvironment of lymph nodes (LN) and solid cancers. Squamous cell carcinoma (SCC) of the
tongue is a prevalent tumor of the head and neck region with high propensity for LN metastasis. The extent of LN
metastasis is the most reliable adverse prognostic factor. Primary tumors can induce vasculature reorganization
within sentinel LN before the arrival of tumor cells and HEV represents these remodelled vessels. This study aims to
evaluate the cancer induced vascular changes in regional lymph nodes (LN) of patients by studying the
morphological and functional alterations of HEV and its correlation with clinical outcome and pathological features.
Methods: This study was based on 65 patients with SCC tongue who underwent primary surgical treatment
including neck dissection. The patients were categorized into 2 groups based on the presence of malignancy in
their cervical lymph nodes. A review of the patients' pathological and clinical data was performed from a
prospective database. Immunohistochemical staining of the tissue blocks for HEV and high-power-field image
analysis were performed and analyzed with correlation to the patients' clinical and pathological features.
Results: The total number of HEV was found to be significantly associated to disease-free interval. There was a
similar association comparing the HEV parameters to overall survival. The density of abnormal HEV was significantly
higher in patients with established metastases in their lymph nodes and HEV was shown to be a better prognosis
factor than conventional tumor staging. The HEV morphological metamorphosis demonstrates a spectrum that
correlates well with disease progression and clinical outcome.
Conclusions: The results suggest that the HEV displays a spectrum of morphological changes in the presence of
cancer and LN metastasis, and that HEV is possibly involved in the process of cancer metastasis. We revealed the
relationship of HEV and their metamorphosis in pre-metastatic and metastatic environments in regional lymph
nodes of tongue cancer patients in relation to clinical outcomes. The significant observation of modified dilated
HEV containing red blood cells in lymph nodal basin of a cancer suggests the shifting of its function from one
primarily of immune response to that of a blood carrying vessel. It also demonstrated potential prognostic value.
More studies are needed to elucidate its potential role in cancer immunotherapy and as a potential novel
therapeutic approach to preventing metastasis by manipulating the remodelling processes of HEV.
Keywords: High endothelial venules, Cancer metastasis, Angiogenesis, Lymph nodes* Correspondence: seryee@yahoo.com
1Department of General Surgery, Singapore General Hospital, Singapore,
Singapore
2National Cancer Centre Singapore – Van Andel Research Institute,
Translational Research Laboratory, Division of Medical Sciences, National
Cancer Centre, Singapore, Singapore
Full list of author information is available at the end of the article
© 2012 Lee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lee et al. Journal of Translational Medicine 2012, 10:206 Page 2 of 13
http://www.translational-medicine.com/content/10/1/206Background
Cancer research has focused significantly on the patho-
genesis of metastasis as the presence of metastases often
translate to a poor prognosis with relatively few effective
therapeutic measures.
Oropharyngeal carcinoma is ranked among the top ten
most common cancer diagnosed in men in the United
States [1]. Of all the carcinomas of the head and neck,
tongue is the most prevalent site. The 5-year survival
rate for oral cancer has not improved significantly over
the past several decades and remains at 50–55%, despite
current advances in surgery and radiation therapy [2,3].
This is primarily because mortality results from meta-
static disease and local recurrence.
The first draining lymph node was coined the “sentinel
node” 3 decades ago by Cabanas, who defined the concept
of the sentinel node being the doorway to the regional
node basin [4]. Sentinel lymph node (SLN) metastasis is
the preliminary process in the spread of cancer in many
malignancies. The sentinel lymph nodes undergo morpho-
logical and functional changes induced by the primary
tumor. Some of these changes are brought into effect by
vasculature and lymph channel reorganizations before the
arrival of cancer cells and the key blood vessels in such
lymph nodes (LN) that are remodeled are identified as
high endothelial venules (HEV) [5]. Tumor-reactive
lymphadenopathy in SLN has been observed for decades,
but alterations of the lymphatic channels and vasculature
in these nodes before the arrival of metastatic tumor cells
remain poorly characterised [6,7].
High endothelial venules and its role in cancer metastasis
There is emerging data elucidating the potential role of
specialized blood vessels called HEV in cancer, either as a
prognostic factor or as a potential modulator or target
in tumor immunotherapy [5,6,8-10]. High endothelial
venules are specialized post-capillary venules found in
lymphoid tissues, located mainly in the T-call zones such
as the para-cortical areas of LN. They are morphologically
and functionally distinct from ordinary venules and after
the vascular endothelial cells (EC) of the blood–brain bar-
rier, the EC of HEV are the next most well characterized.
Each HEV has a prominent peri-vascular sheath; a thick
basal lamina and the layer of ECs are tall and plump in
appearance [9,11]. High endothelial venules were first
characterized and studied extensively in the field of im-
munology. The evidence suggests that HEV has a central
role in lymphocyte trafficking to LN, allowing the en-
trance of native L-selectin high cells in to the LN paren-
chyma and this is largely mediated by chemokines
produced in and around HEV such as the peripheral node
addressins (PNAds). There is a synchrony between HEV
and lymphatic vessels as seen in immunization studies,
which reveal that the lymphoid tissue microenvironmentis crucial for the maintenance of HEV characteristics dur-
ing homeostasis and the close association in time, func-
tion and space between lymphatics and HEV in the
remodeling process after immunization indicate that the
two systems are closely related and engage in cross-talk
through various factors [9,12-14]. The LN undergo re-
modeling with changes in complex kinetics of lymph flow,
cell content flow, blood flow, HEV gene expression as well
as morphologically [12]. Recently, with animal models, it
was shown that before the arrival of metastasis in the
SLN, there are reorganizations of vasculature and lymph-
atic channels resulting in the SLN becoming a functional
blood vessel enriched organ [5]. These prominent blood
vessels are identified as remodeled HEV. The role of HEV
in immune function and in a cancer metastasis micro-
environment has some differences. In inflammatory con-
ditions, the chief role of HEV in the traffic control of
lymphocytes is evident from the presence of lymphocytes
in the dilated lymphatic sinuses [9,13]; whereas in tumor-
reactive lymphadenopathy, there are few cells, suggesting
a different process. There are also studies in murine mod-
els to suggest that the movement of tumor cells to LN
resembles the normal migration of dendritic cells during
immune stimulation, resulting in the term “Tumor cell
trafficking” [9,15]. This observation, coupled with the
knowledge of the intimate relationship between HEV and
lymphatic vessels in LN leads to our proposed hypothesis
that HEV might provide the shortcut or a bypass route
connecting the vascular and lymphatic system at the level
of the SLN. This shortcut route is a speculative hypothesis
and requires further research. This study aims to provide
some preliminary observations in the changes of HEV
morphology in a cancer environment and to provide some
consistent clinical and morphological data to support our
hypothesis [10]. This is in contrast to the traditional Hal-
stedian philosophy that an enbloc resection of the primary
cancer and its regional lymphatic basin will achieve cure
as its assumption is that tumor cells follow a stepwise
pathway, from the primary tumor to the regional lymph
nodes and to the next echelon and then to the systematic
circulation through distal lymphaticovenous connections
such as the thoracic duct. While this orderly fashion is
true in the majority of the time, this stepwise progression
is not strictly followed as shown in clinical follow-up stud-
ies, where up to 20% of women with node-negative breast
cancer go on to develop distant metastases [16,17]. This is
consistent with the analysis of sentinel lymphadenec-
tomies suggesting that 20% of systemic metastases are
derived from cancer cells that bypass this orderly lymph-
atic route [18]. The HEV providing the vehicle of this
shortcut route for cancer cells might account for this ob-
servation in this subset of these patients [6].
In addition to this hypothetical role of providing the
physical shortcut route in the LN, evident from the
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within the HEV and significant increase size of its lumen
in the presence of a tumor, hints that HEV presumably
functions like a blood vessel in anticipation to supply the
needs for an accelerating growth of a soon-to-arrive
tumor deposit [5,10].
Objectives of study
We aim to evaluate the tumor-induced vascularization
in regional LN of the patients with tongue cancer, specif-
ically looking at HEV. We also seek to confirm the mor-
phological and functional alterations of HEV in the
regional lymph nodes of the patients with carcinomas of
the tongue and correlate these findings with clinical out-
come. The key blood vessels involved in LN in a cancer
setting are HEV, with its function shifting from immune
response to one as a blood flow carrier. We hypothesize
that the transformation of HEV in the presence of can-
cer is a spectrum and these morphological features of
altered HEV correlate with clinical outcome of patients,
establishing its pivotal role in the pathogenesis of metas-
tasis [6]. This association will serve HEV as a novel
prognostic marker and a potential candidate for thera-
peutic targeting.
Methods
Approval was obtained from the Institutional Review
Boards of both institutions involved in the study (2007/
464/B). The study population consisted of 175 consecu-
tive patients with SCC of the head and neck who had
received primary surgical treatment at the Department
of General Surgery, Singapore General Hospital and the
Department of Surgical Oncology, National Cancer Cen-
ter, Singapore, from January 2001 through to December
2005. The patients’ pathological and clinical data includ-
ing follow-up information was reviewed from a pro-
spective database. The inclusion criteria included all
surgically treated patients with histologically proven
SCC tongue who underwent a neck dissection, with a
minimum of 2-year follow up period. Patients with a sec-
ond primary cancer and patients who did not have a neck
dissection as part of their primary treament were
excluded. There were a total 65 patients that met the
study inclusion criteria. There were 35 patients in the
group with primary SCC tongue without pathologically
proven lymph node metastases in their neck dissection
specimen who were designated as “cases”, and 30 patients
in the group with primary SCC tongue with pathologically
proven lymph node metastases in the neck dissection spe-
cimens, who were designated as “controls”. All patients
included had radical excision of the primary tongue
lesion and a neck dissection according to depart-
mental protocol. In both groups, all patients had
radical enbloc excision of the primary tongue lesionwith or without resection of adjacent structures with
either a unilateral or a bilateral, supraomohyoid neck dis-
section or a modified radical neck dissection. Tumours
were classified according to the AJCC TNM Staging Clas-
sification, based on a pre-operative clinical evaluation and
this determined the type of neck dissection performed by
the primary surgeon [19]. All cases were discussed at a
multi-discplinary head and neck tumor board. Intra-
operative frozen sections were performed for margins of
the tongue lesion and further resection of the tongue was
performed in event that the surgical margins were
involved. Upon discharge from the hospital, they were fol-
lowed up at regular intervals of monthly, 3-monthly,
6-monthly and yearly at a progessive rate. Inpatient and
outpatient clincal data, pathological, radiological and
operative records were retrieved from a central med-
ical records office and from the Department of Path-
ology, Singapore General Hospital. Mortality data
was obtained and confirmed from the hospital cen-
tral medical records office as well as the Singapore
Registry of Births & Deaths.
Immunohistochemistry
A histological review and analysis of the primary SCC
tongue lesion and their respective lymph node tissues in
the neck dissection specimen from the 65 cases of
tongue cancer patients was conducted. The lymph node
tissues in each case were separated into levels according
to their anatomical locations. The tumor and the neck
dissection paraffin tissue blocks from the selected
patients were retrieved from the Department of Path-
ology, Singapore General Hospital. An independent head
and neck pathologist reviewed the histological specimens
and selected the 3 largest lymph node in both groups for
staining of the HEV. The largest 3 LN were chosen as
the size of a lymph node correlates with the degree of
tumor lymphadenopathy and in the cases of the non-
metastatic neck, the degree of reactive lymphadenop-
athy. Optimisation of the immunohistochemical staining
protocol and subsequent staining of the HEV using the
purified rat anti-mouse MECA-79 (PNAd) antibody (BD
PharMingen, CA, U.S.A), which is specific for HEV, was
performed [5,20].
Computer assisted image analysis
The digital capture of the HEV images and the quantita-
tive image analyses were performed using the slide scan-
ner (ScanScope, Aperio T3; ScanScope Console v. 9.0.
Aperio Technologies, Vista, CA U.S.A) utilising an illu-
minator(Fiber-Lite DC-950, Dolan Jenner, Boxborough,
MA, U.S.A). We analyzed snapshots of the largest 3
lymph nodes under 10x magnification. The total number
of HEV, abnormal HEV (defined as having a lumen area
of 80 square microns) and the HEV with presence of red
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ware (Image J programme with cell counter plug-in,
NIH, Bethesda, MD U.S.A) [21]. The lumen size of 80
square microns was selected as it is the minimum lu-
minal cross-sectional area for functional vessels, corre-
sponding to the minimum caliber of physiologic venules
[5]. An average value for each of these parameters was
calculated for each LN. These 3 values were correlated
to the size of its respective LN and the patient’s clinical
outcomes, namely the overall survival, disease-free inter-
val and recurrence rate.
Definitions of the HEV’s parameters and ratios
This is represented by the following alphabets A, B and
C (Figure 1).
 number of all HEV : A
 number of dilated HEV (defined as lumen size more
than 80 square micron) : B
 number of dilated HEV with red blood cells (RBC)
within its lumen : C
In addition to these three parameters, we also analyzed
the ratios of these abnormal HEV (B and C) with respect
to the total number of HEV (A). This is summarized
below as
 Ratio of dilated HEV to the total number of HEV :
B/A
 Ratio of dilated HEV with RBC within its lumen to
total number of dilated HEV : C/B
 Ratio of dilated HEV with RBC within its lumen
with respect to total number HEV : C/A
Statistical analysis
Correlating the clinical information from our prospect-
ive database, we analyzed the 3 parameters (A, B, C) and
the 3 ratios (B/A, C/B, C/A) with respect to severalAll HEVs (A)
Dilated HEVs (B)
Dilated HEVs with rbcs
within its lumen (C)
Figure 1 The different High endothelial venules parameters.
Venn diagram illustrating the relationship between the different HEV
parameters (A, B, C).clinical parameters, namely Disease-Free Interval (DFI)
and Overall Survival (OS) in the 2 groups (Cases vs.
Controls) and as a single cohort. We used Cox’s Propor-
tional Hazard Model for analysis. In the secondary ana-
lysis, we analyzed the 3 parameters (A, B, C) and the 3
ratios (B/A, C/B, C/A) with tumor characteristics. A
non-parametric test, Wilcoxon-rank-sum test, was per-
formed to test the difference on HEV and its parameters
as well as 3 ratios between the 2 groups of patients. A
non-parametric test, Kruskal-Wallis test, was performed
to test the difference on the HEV as well as 3 ratios
among different stages. All p-values of < 0.05 were con-
sidered statistically significant.Results
The association of HEV and clinical outcome was stud-
ied by initially analyzing the OS and DFI of the 2 groups
prior to individually analyzing the various HEV para-
meters (A, B, C, B/A, C/B, C/A) against OS and DFI.
The details of the preliminary results comparing HEV
parameters and patient outcomes have been previously
published in an earlier paper [20]. In the secondary ana-
lysis, we further analyzed the tumor pathological charac-
teristics (i.e. primary tumor volume, the stage of the
disease and grade of the tumor) against clinical outcome
(OS and DFI), to determine if these conventional tumor
factors were prognostic in nature. We further investi-
gated the role of HEV and its prognostic value by com-
paring and analyzing the HEV parameters with respect
to the tumor volume, grade and stage. These analyses
were repeated without controlling for the group factor
(i.e. taking the sample population as a single cohort). Fi-
nally, we investigated the HEV parameters in each group
to determine if there was a difference in the HEV values
in the presence or absence of metastasis in the LN.
We analyzed the DFI and OS of the 65 patients with
respect to their groups (35 cases versus 30 controls) to
estimate the relative risk of DFI and OS associated with
the group.Overall survival analysis
The relative risk of OS of cases was estimated to be
0.229 times of the risk of control group based on the
study sample (95% C.I. 0.048 ~ 1.102). Patients with
presence of metastases in their regional cervical LNs had
a 4.367 times risk of mortality as compared to patients
without metastasis. The Kaplan -Meier curves were sig-
nificant in terms of overall survival time between con-
trols and cases (p = 0.046) (Figure 2). There was no
significance detected found in the total no. of HEV (A);
no. of dilated HEV (B); no. of dilated HEV with RBC
inside its lumen(C) or any ratios(B/A, C/B, C/A) with
respect to the overall survival (Table 1).
p-value = 0.046
Figure 2 Kaplan Meier overall survival curves for the two groups (Cases vs. Controls).
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Similarly, we compared the DFI between the 2 cases and
controls. The risk of cases was estimated to be 0.75
times of the risk of control group based on the sample
(95% C.I. 0.342 ~ 1.644). This implied that in patients
without LN metastases, if recurrences occur, the DFI
tend to be longer. However, this did not achieve statis-
tical significance (p = 0.472) (Figure 3).Table 1 Summary of results
HEV parameters
Total no. of HEV (A)
Total no. of HEV (A) and Disease Free Interval (as a Cohort)
Dilated HEV (B)
HEV with RBC within its lumen (C)
Ratio of dilated HEVs to the total no. of HEV(B/A)
Ratio of dilated HEVs with RBC to total no. HEV (C/A)
Ratio of dilated HEVs with RBC within its lumen to total no. of dilated HEV
(C/B)There was a significant association of number of
HEVs (A) to the disease free interval (DFI). This was
statistically significant when controlling for the group
factor (p-value = 0.022), and when analyzing as a sin-
gle cohort (p-value = 0.023). However, there was no
significance detected found in the other HEV para-
meters in relation to DFI, namely no. of dilated HEVs




Overall Survival 1.024 0.471 0.961 ~ 1.091
Disease Free
Interval
1.051 0.022 1.007 ~ 1.097
Disease Free
Interval
1.051 0.023 1.007 ~ 1.096
Overall Survival 1.071 0.476 0.886 ~ 1.295
Disease Free
Interval
1.034 0.594 0.915 ~ 1.169
Overall Survival 1.116 0.345 0.889 ~ 1.401
Disease Free
Interval
1.044 0.584 0.896 ~ 1.216
Overall Survival 1.078 0.982 0.002 ~ 638.23
Disease Free
Interval
10.10 0.450 0.001 ~ 39.89
Overall Survival 3.624 0.737 0.002 ~ 6634.42
Disease Free
Interval
4.67 0.643 0.001 ~ 145.83
Overall Survival 17.884 0.171 0.287 ~ 1114.67
Disease Free
Interval
5.458 0.208 0.389 ~ 76.616
p-value = 0.472
Figure 3 Disease free interval curves for the two groups (Cases vs. Controls).
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spect to DFI (Table 1).
Secondary analysis
Tumor pathological data, namely primary tumor vol-
ume, the stage of the disease and grade of the tumor
were analyzed against OS and DFI, to determine if these
conventional tumor factors were prognostic in nature.
We did not detect any prognostic value of tumor vol-
ume; stage or grade that reached statistical significance
(Table 2). As part of the secondary analysis, we com-
pared the HEV parameters in the 2 groups as well as theTable 2 Summary of secondary analysis results
Tumor characteristics Clinical data Relative risk p
Tumor volume (TV) Overall Survival 0.985 0.476
Disease Free Interval 0.990 0.481
Stage (S) Overall Survival 1.116 0.710
Disease Free Interval 1.302 0.348
Grade(G) Overall Survival 0.882 0.815
Disease Free Interval 1.436 0.308
Since there are no statistical difference noted between the 2 groups, we
now consider the 2 groups (Cases and Controls) as a cohort © and
repeat the analysis summarized below
Tumor volume (TVc) Overall Survival 0.994 0.765
Disease Free Interval 0.994 0.648
Stage (Sc) Overall Survival 1.364 0.237
Disease Free Interval 1.209 0.255
Grade(Gc) Overall Survival 1.121 0.822
Disease Free Interval 1.493 0.221HEV parameters to the tumor characteristics (tumor
stage and its grade only; tumor volume being a continu-
ous variable was excluded). There was no significance
detected in either stage or grade of tumor with regards
to the HEV parameters. In the final part, we investigated
the various HEV parameters in each groups to if there
was a difference in the HEV values in the presence or
absence of a metastasis in the LN. The average ratio of
dilated HEV with RBC within its lumen to total no. of
dilated HEV (C/B) in control groups was statistically sig-
nificantly higher than that in case group (p = 0.0318)
(Table 3).
Discussion
Squamous cell carcinoma of the tongue has one of the
fastest rising rate today affecting the young with a high
propensity for LN metastases. [22] The presence of
metastatic cells in regional LN, along with extracapsular
spread are the most important prognostic factors in
patients with squamous cell carcinoma (SCC) of the
tongue [22-25]. The prognosis is worse compared to
other equivalent carcinomas of the head and neck
region.
Tumor cell metastasis to regional LN marks one of the
initial steps in the cascade of tumor metastasis after tumor
cell progression in the primary tumor. The lymphatic
metastatic cascade is a series of complex interrelated steps
and processes [26]. As the tumor grows and enlarges,
cytokines are secreted to promote lymphangiogenesis
[27]. As malignant cells invade the extracellular matrix,
they enter the lumen of the lymphatics and they move in
clusters or as single cells to the first echelon of regional
Table 3 Comparing high endothelial venules parameters in the 2 patient groups
HEV parameters Control Case p value
Mean/standard error (n = 30) (n = 35) p>0.05
Total number of HEV (A) 40.085 / 1.83 41.305 / 1.59 p>0.05
Ratio of dilated HEV to the total number of HEV (B/A) 0.149 / 0.0086 0.166 / 0.0186 p>0.05
Ratio of dilated HEV with RBC within its lumen with respect to total no. HEV (C/A) 0.098 / 0.0078 0.101 / 0.0135 p>0.05
Ratio of dilated HEV with RBC within its lumen to total no. of dilated HEV (C/B) 0.646 / 0.0301 0.582 / 0.0275 p=0.0318
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properties, such as the lack of basement membrane in ter-
minal lymphatics, the presence of the intercellular clefts,
the traumatic environment in the blood including shear
forces of blood turbulence and tumor antigenicity detec-
tion by host immune cells, contribute and account for the
observation that in many solid cancers, lymphatic metas-
tasis precedes metastasis via the vascular system [26,30].
The relationship between angiogenesis and lymphangio-
genesis has been extensively studied in cancer research
[14,26,31,32]. This is pertinent in the biology of LN metas-
tasis where the two systems literally lie side by side. There
is extensive evidence showing members of the Vascular
endothelial growth factor (VEGF) family, namely VEGF-
C, VEGF-D and VEGF-A [33], are not only important reg-
ulators of lymph vessel growth in vivo, but may also be
involved in the process of promoting lymphatic metasta-
sis, such as VEGF-C [27,34-36]. This is significant because
there is evidence that tumor can activate both LN lym-
phangiogenesis and angiogenesis before metastasis, and
this would translate into logical efforts in the field of anti-
cancer research specifically targeting pathways of tumor
lymphangiogenesis and angiogenesis. There have been en-
couraging results from therapeutic targeting of the various
VEGF member pathways to inhibit lymph node metasta-
sis, reduce lymphatic and vascular density in LN as well as
to reduce overall tumor burden in the lymph nodes and
distant metastases [34,37,38].
Targeted therapy such as anti-angiogenesis drugs has
shown positive results in clinical studies. Bevacizumab
(AvastinTM), a monoclonal antibody to VEGF-A, was
approved by United States Food and Drug Administra-
tion (FDA) in 2004 and has proven clinical benefits in
treatment of metastatic colorectal cancer when the drug
was added to standard chemotherapy and also has posi-
tive results in metastatic kidney cancer and advanced
lung cancer. There are many ongoing trials including
Phase III clinical trials in advanced or metastatic renal
cell carcinoma, pancreatic cancer, and ovarian cancer for
AvastinTM [39]. Other molecular pathways that harbor
potential targets which have varying degrees of anti-
angiogenesis and anti-lymphangiogenesis properties, are
ligands such as hepatocyte growth factor (HGF), recep-
tors like Neuropilin 2, PDGFRα/β and others such as
Angiostatin, interferon α/β and platelet-factor 4 [40].Two other antiangiogenic drugs, Sorafenib (Nexavar™,
Bayer) and Sunitinib (Sutent™, Pfizer), have also been
approved by the FDA for various aspects of cancer treat-
ment, for example, Sorafenib and Sunitinib have been
beneficial in the treatment of metastatic renal-cell cancer
and advanced hepatocellular carcinoma [41,42]. They
target multiple receptor tyrosine kinases, including
VEGF receptors and platelet-derived growth factor
(PDGF) receptors [43].
In our series, we detected a statistical significance when
we analyzed the OS but not in DFI in the patients with
or without LN metastasis (cases vs. controls) (Figures 2
and 3). This may be attributed to our limited sample size.
It has been proposed and is currently being validated, that
SLN biopsy may play the next stage in the evolution in
the neck management and treatment of tongue SCC [44].
Exploration and understanding of this concept coupled
with advances and optimistic results in anti-angiogenesis
therapy involving VEGF anti-metabolites translates the
next logical exploration to be invested in the study of the
pathogenesis of lymph node metastasis. It was shown that
the lumen of the lymphatic sinuses and blood vessels were
dilated in SLN before metastasis [5]. We have demon-
strated that lymph nodes are transformed by the primary
tongue tumor to become a functional blood vessel–
enriched organ before and independent of metastasis, with
the changes in the morphology of the HEV to become
main blood flow carrier in the lymph node (Figure 4). This
process of vascularization in the LN (HEV morphological
alterations) appears similar and consistent in human tis-
sues and previous animal models [5,20]. This study pre-
sents functional and structural data that the primary
tumor can possibly manipulate the microenvironment and
biology of lymph nodes to potentially facilitate the prolif-
eration of subsequent tumor deposits leading to estab-
lished metastases. The morphological alteration of HEV in
the presence of a cancer, coupled with the increased pro-
liferation rate of the endothelial cells, results in a func-
tional shift and phenotypic change of HEV from its
known function as a lymphocyte recruitment modulator
to one as a blood carrier.
In previous studies, the degree of lymphatic dilation in
the SLN significantly correlated with the primary tumor
weight [5,10]. This observation suggests that the lymph-
atic fluid from the primary tumor induced the persistent
Figure 4 Dilated HEVs with red blood cells in its lumen (high
power field).
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consistent with findings that demonstrate, in contrast to
angiogenesis, in which blood flow proceeds only after the
vessel develops, lymphangiogenesis can be induced by
interstitial fluid channeling [45]. In this aspect, this is
analogous to immunology studies showing the alteration
of lymph channels in SLN can also occur during an in-
flammatory reaction, which facilitates the migration of
inflammatory cells [46,47] The difference in cancer metas-
tasis biology and inflammatory process starts here. In
endotoxin induced experiments and immunology studies,
the dilated lymphatic sinuses and vessels in the associated
reactive LN were full of lymphocytes. In contrast in
tumor-reactive lymphadenopathy, the lymphatics con-
tained minimum or no cellular material, suggesting differ-
ent roles of the SLN lymphatic channels in different
pathologic processes. It has been well characterized that
the HEV of lymph nodes play an important role in recruit-
ing lymphocytes for the generation of immune responses
[9,11]. By expressing homing receptors on their surface,
which blood lymphocytes can recognize as they pass in
circulation, HEV provide a unique location where naive
lymphocytes can enter the lymph node [47,48].
In our previous study [5], we found that the role of
HEV was transformed from a lymphocyte recruiter to
become the main blood flow carrier in the SLN prior to
metastasis. We have shown in this study that in the
regional cervical LN, not only could the morphology of
individual HEV change dramatically to increase blood
flow, but the proliferation rate of HEV endothelial cells
was also increased before metastasis. This transform-
ation of HEV as a lymphocytic carrier in LN to a blood-
flow carrier can be seen in the large quantity of red
blood cells visible in the HEV even in pre-metastatic re-
gional LN. More significantly, this phenomenon is also
more pronounced in the regional LN of the patientswith established LN metastasis. This is consistent with
the findings of Chung and colleagues demonstrating the
increased HEV density in SLN of oral SCC before the ar-
rival of tumor cells, the HEV density in metastatic SLN
was also higher than that of non-metastatic SLN [6]. We
have shown this in our supplementary data that patients
with lymph node metastases have more dilated HEV
with RBC in their LN as compared to patients without
LN metastasis. The average ratio of dilated HEV with
RBC within its lumen to total no. of dilated HEV(C/B)
in the control (pN+) group is statistically significantly
higher than that in case group (p-value = 0.0318).
In addition, with the benefit of patients’ pathological
and follow-up information, we have demonstrated that
even with just an increase of 1 HEV in a high-power-
field (HPF), regardless of the group, the risk is 1.024
times worse in terms of overall survival. This is consist-
ent with clinical knowledge and natural history of the
disease. It is well established that patients without LN
metastases in their regional LN (cases in our cohort)
have a significantly better prognosis, and; this fact is also
reflected in our analysis [22,49-51] (Figure 2). Cases had
a 0.428 times the risk of Controls with regards to overall
survival if they had the same number of HEV. It is cru-
cial to understand that this risk is exponential in nature.
To illustrate the significance of this result, an example
will be used: Patient A with tongue SCC has proven LN
metastases in the cervical LN. On further immunohisto-
chemical staining, it is found that he has 0 HEV in a
random high-power-field. Comparing this to patient B
who has the same grade, stage of tumor, degree of LN
metastases as patient A but has 100 HEV in a HPF, pa-
tient B will have a [ (1.024)100 = 10.715 ] 10 times worse
prognosis in OS as compared to patient A. We will then
consider patient C who has tongue SCC with no LN
metastasis. If the HEV amount in a HPF is the same as
either patient A or B, patient C’s risk as compared to ei-
ther patient A or B will be 2.34 times (1/0.428= 2.34)
better in terms of overall survival (Table 4). Although
this did not reach statistical significance (p=0.471), we
believe this to be a factor of a small sample size.
Assuming that our hypothesis is true, HEV trans-
formation from a normal immunological mediator to a
tumor metastasis mediator is reflected by morphological
changes from a normal appearing HEV, to a dilated
HEV, and then to a dilated HEV containing RBC. We be-
lieve that this metamorphosis occurs on a spectrum, and
this process begins with the HEV increasing in absolute
numbers, then each becoming more dilated before pro-
gressing into a functional vessel carrying blood (Figure 5).
Hence we analyzed our data looking at the 3 different
stages of HEV transformation and the ratio comparing
each parameter in a systematic way to demonstrate this
spectrum (Figure 1).
Table 4 Differences in OS and DFI relative risk in the 2 groups
Patient group Number of normal HEV(A) in a HPF OS Relative risk DFI Relative risk
Control 0 1.00
1 (patient A) 1.024 1.051
100 (patient B) (1.024)100 = 10.715 (1.051)100 =144.634
Case 0 (patient C) 0.428 0.732
1 0.428 × 1.024 = 0.435 0.732 × 1.051 = 0.769
100 0.428 × (1.024)100 = 4.586 0.732 × (1.051)100 = 105.872
Figure 5 Metamorphosis of High endothelial venules in a tumor microenvironment. This process begins with the high endothelial venules
increasing in absolute numbers, subsequently each of them becoming more dilated and lastly every one of them will become a function vessel
carrying blood.
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Figure 6 Overall survival relative risk with respect to the
different high endothelial venules ratios.
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that a patient’s OS risk is 1.024 times worse than an
equivalent patient if there is 1 more HEV in one HPF of
his regional LN, the risk is increased to 1.071 if the HEV
is a dilated HEV. The risk is even higher at 1.116 times
if the HEV is a dilated HEV containing RBC (Table 1)
[20]. This trend is also seen when all patients are consid-
ered in a single cohort. A patient’s OS risk is worsened
by 1.004 times if there is an increase of 1 dilated HEV in
a HPF. If that dilated HEV contains RBC, the OS risk is
increased to 1.008 times.
In the treatment of tongue carcinomas, DFI is important
as it signifies the failure of loco-regional control for which
there is little effective therapy. Further surgery e.g. neck
dissection to remove loco-regional recurrences is plagued
with high morbidity and mortality. This, coupled with
poor chemotherapy and radiotherapy response rates in
recurrences, often equates to rapid deterioration of the
patient’s condition. Disease free interval was also analyzed
in the same manner to the three different HEV morpho-
logical phenotypes.
We found statistical significance in the relationship be-
tween the total number of HEV (A) and DFI when we
controlled for the group (i.e. taking in the presence of
LN metastasis as a factor). (p=0.022). This significance is
preserved when we analyzed all the patients as a cohort
(p=0.023) [20]. This means that the quantity of HEV is
inversely related to DFI. If you consider the LN status
and take it into statistical consideration, if there is one
more HEV in a HPF, the DFI is 1.051 times worse than
zero HEV. It is again important to note that the relation-
ship of the quantity of HEV with respect to DFI is expo-
nential in nature. For example, a patient (patient B) with
100 more HEV (A) in one HPF has a {(1.051)100 =144.634}
144 times shorter DFI as compared to an equivalent pa-
tient with only one HEV per HPF (patient A) (Table 4).
Excluding the group effect and considering all the patients
as a cohort, a patient with 1 more HEV per HPF will have
a DFI that is 1.051 times worse than a patient with zero
HEV in a HPF (p=0.023).
We looked at the different ratios of abnormal HEV
and compared them to several clinic-pathologic para-
meters namely overall survival, disease–free interval,
tumor volume, stage and grade of the tumor. The details
are specified in the secondary results (Table 2).
There is a general trend observed. The more advanced
the disease, the higher the ratio/percentage of abnormality
of HEV. This can be seen in when we analyzed OS and
the 2 ratios. The OS relative risk worsens by 1.078 if the
ratio B/A (ratio of dilated HEV to the total number of
HEV) increased by 1, while the OS relative risk worsens
by 3.624 times if the ratio of dilated HEVs with RBC to
the total number of HEV increases by 1. Most import-
antly, if we consider the most abnormal form of HEV(dilated HEV with RBC within its lumen, C) and look at it
as a ratio to the total no. of HEV, a patient’s OS relative
risk worsens by 17.884 times if this ratio (C/A) increases
by a factor of 1. This observation approaches marginal sig-
nificance. (p = 0.171) (Figure 6).
In this study, we have shown the relationship of HEV
and their transformation in a cancerous environment.
We also note that in previous studies the HEV morph-
ology did not alter at all in endotoxin-induced lymph-
adenopathy, implying a selective reaction of HEV in the
cancerous condition [5]. Distinct, differentiated gene ex-
pression has also been reported when the endothelial
cells respond to the changing of their microenvironment
[52]. In a previous study, it was shown that the cellular
morphology of the tall endothelial cells forming HEV
changed dramatically to become flat endothelial cells in
the presence of cancer. As a consequence, the HEV was
remodelled from a thick-walled, endothelial vessel with a
small lumen to a thin walled, large-lumen vessel shifting
its function from recruitment of lymphocytes to becom-
ing a blood vessel (Figure 4) [10]. These facts indicate
that the blood vessel endothelium has tremendous po-
tential to adapt its environment. The confined lymph
and blood channel alterations within the SLN, but not in
the next station lymph node, imply that an inducer from
the primary tumor is functioning locally with the exist-
ence of an active primary cancer. VEGF-A has been
found to be an inducer of lymphangiogenesis in SLN
[33]. Other studies have shown that serum level of
VEGF-A was elevated in patients with late stage NPC
[21] VEGF-A is a secreted protein factor that can travel
in blood to other lymph nodes, these findings suggest
that there may be other inducers involved. It is also of
interest to explore the role of HEV after the establish-
ment of a metastatic tumor nest. The enlarged, remod-
elled HEV could integrate into the metastatic tumor
vasculature with further differentiation, characterized by
the gradual loss of their specific marker MECA-79 from
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tumor nest. [5,10] It has been explained that, compared
with primary tumors, the more rapid growth of meta-
static lesions in the cervical lymph nodes of NPC
patients was due to clonal selection of the cancer cells
during metastases, with highly proliferative clones disse-
minated to the cervical nodes. However, based on our
findings, the metastatic tumor vasculature in lymph
nodes consists of many large blood vessels derived from
normal HEVs, suggesting that the efficiency of nutrition
and oxygen supplies could be better for the metastatic
tumor cells in the involved lymph node. The enrichment
of the blood supply in the lymph node before and after
metastasis may favor the growth of newly arriving meta-
static cancer cells. Consequently, as evident clinically in
the long term follow-up of cancer patients, the involved
regional lymph nodes may become manifest first,
whereas the primary tumor remain clinically occult for
years [53]. Moreover, the high density of functioning
blood vessels in lymph nodes may subsequently facilitate
the metastasis of cancer cell to distant organs. Con-
versely, consistent with its role in lymphocyte trafficking,
if the HEV density is increased in the tumor themselves
as opposed to LN, it has favorable prognostic value,
Martinet et al. reported that in 146 breast cancers, the
density of tumor HEV was an independent prognostic
risk factor for DFI and OS [8]. This further suggests the
tumor HEV function as major gateway for lymphocyte
infiltration into tumors and represents potential targets
for cancer immunotherapy. It will also be important to
elucidate if the highly vascularized premetastatic SLN is
associated with an increased metastatic potential. Con-
trol of lymphatic fluid movement may also be a target to
consider in preventing metastases.
Assuming our hypothesis is true with regards to the
role of HEV in cancer metastasis, a potential therapeutic
approach is to interrupt or block this remodelling
process and evaluate if there is an effect on metastasis.
This will confirm the HEV’s central role in the patho-
genesis of metastasis.
Further studies need to designed and performed to elu-
cidate the pathways of HEV transformation. A control
gene for the growth and differentiation of HEV remains to
be identified [9]. With regards to this, a recently identified
nuclear factor (NF), NF-HEV has potential because it is
preferentially expressed by HEV [54]. Dendritic cells, well
known for their antigen presentation roles has recently
been shown to modulate the phenotype of HEV and con-
trol entry of naive lymphocytes to LN, their role in a can-
cer microenvironment is also an area of potential research
[13]. There are recent experiments in mouse models in-
vestigating conditional gene targeting of HEV as well [55].
Identification and characterization the molecular path-
ways and the control genes would have considerableclinical applications. For example, it would enable the de-
sign of experiments and studies to induce or retard the
formation of HEV in various tissues, including tumors
and their LN, improving vaccination strategies against
pathogens and cancers. Therefore, there is a wealth of
translational applications with regards to targeting HEV as
a ligand for cancer investigational therapeutics. It paves
the journey in the discovery of many unknown genes and
molecules with potential clinical importance. Lastly, more
work can be performed to validate our findings in other
solid cancers.
Limitations
Our study did find some preliminary associations in
HEV with regards disease pathology and clinical correla-
tions and demonstrated the HEV phenotype changes in
cancer; however, it is premature to draw any strong con-
clusions. Our study has limitations and there are mainly
associated with 2 major factors. It is a retrospective
study with a limited sample size and its lacks a molecu-
lar experimental component.
It is an investigative and proof-of-concept study as the
exact role of HEV role in cancer metastasis is still under
investigation. The limited sample size of 65 patients is
derived over a period of 5 years and it is a subset of a large
group selected from the Head and Neck service database
in 2 large tertiary institutions. This sample population size
was deemed to be sufficient to show a significant differ-
ence in their overall survival between the 2 study groups.
Nonetheless, in an effort to reduce confounders and errors
in the interpretation of our results, a strict selection cri-
teria was applied to obtain a more homogenous group.
Due to the small sample size, we believe that some of the
associations in our hypothesis did not reach statistical sig-
nificance. The retrospective nature of the study is no
doubt a limitation but as the nature of this study does not
involve therapeutics or a comparison of factors, the retro-
spective nature actually works to our advantage. We are
able to collate a large sample study size with confirmatory
clinic-pathological data within a short period of time and
concentrate our time and effort in the investigative and
analytical aspects.
Secondly, one main investigative feature of our study
concentrated largely on the histopathological assessment
of the patients’ LN status preserved tissue paraffin blocks
in storage. There are limitations to using tissue paraffin
sections and the available techniques have their limita-
tions. There are deficiencies in the consistency of the qual-
ity of the tissue paraffin blocks, some tissue blocks are less
well preserved than others, especially the older blocks
may not be stored in optimal conditions over time. We
use an optimized technique for our immunohistochemis-
try using anti-MECA-79 as our sole antibody for HEV [5].
Ideally we would like to use at least 2 different HEV
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sensitivity inaccuracies in the antibody, however, there is
no other commercially available antibody for HEV to date.
One assumption in the study is that MECA-79’s specificity
and sensitivity is high enough and representative of all
HEV in our tissues. Ultimately, analysis at the level of mo-
lecular genetics will be the critical factor in confirming the
value of immunohistochemical stains in the assessment of
biological behavior and prognosis. A considerable problem
to be overcome is the marked variation in tissue staining
that can be encountered, both in different, patients, neo-
plasms and in different laboratories. These differences
reflect the varied biology of neoplasms, as well as differ-
ences in fixation and technique. These variations make
comprehensive interpretation of the data and results a
worthwhile challenge.
A major limitation in the study is the lack of experi-
mental evidence and results to strengthen our observa-
tory data. The next step in proving our hypothesis is to
establish molecular pathway experiments and studies to
elucidate the pathways and the molecular mechanisms
underlying the phases of HEV’s metamorphosis peri-
metastasis. In order to systematically study the role of
the modified HEV as a blood vessel and a shortcut
mechanism for metastasis, appropriate tracer molecules
with real time imaging technology and xenograft experi-
ments studying the mechanism of the lymph node
microenvironment changes correlating to the spreading
of cancer cells should be pursued. As the objective of
this study is to establish the presence of a correlation be-
tween HEV and clinico-pathological features in cancer
patients, the molecular experiments are not included but
are planned for as stated in our future directions.
Finally, ideally the best controls should include neck
LN dissection specimens in patients without cancer to
optimally illustrate the spectrum of HEV changes from a
normal to a pre-metastatic stage and finally to a meta-
static one however in reality, it is rare to obtain such
specimens and thus not included in the study.
Conclusion
This study demonstrates morphologic and functional
alterations of the HEV to become the main blood flow
carrier in the lymph node. The analysis reveals the rela-
tionship of HEV and their metamorphosis in pre-
metastatic and metastatic environment in regional lymph
nodes of tongue cancer patients in close relation to clin-
ical outcomes. Our findings coupled with studies elucidat-
ing the basis of lymphangiogesis and angiogenesis within
SLN support our hypothesis that HEV play a pivotal role
and may be the elusive junction providing the lymph flow
shortcut route into the systemic circulation at the level of
the SLN. The confirmation of this shortcut and the ex-
ploration of the related molecular mechanism ofestablishing the shortcut will broaden our knowledge
about lymph circulation in cancerous conditions and may
provide novel therapeutic targets.
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